Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
NKD-H82Q3 | Human | Biotinylated Human NKG2D / CD314 Protein, Avitag™,His Tag (MALS verified) |
|
||
NKD-C5248 | Cynomolgus | Cynomolgus NKG2D / CD314 Protein, His Tag |
|
||
NKD-H5257 | Human | Human NKG2D / CD314 Protein, Llama IgG2b Fc Tag, low endotoxin |
|
||
NKD-H82F4 | Human | Biotinylated Human NKG2D / CD314 Protein, Avitag™,Fc Tag (MALS verified) |
|
||
NKD-HF224 | Human | FITC-Labeled Human NKG2D / CD314 Protein, Fc Tag |
|
||
NKD-H5259 | Human | Human NKG2D / CD314 Protein, Mouse IgG2a Fc Tag |
|
||
NKD-H5245 | Human | Human NKG2D / CD314 Protein, His Tag |
|
||
NKD-H5265 | Human | Human NKG2D / CD314 Protein, Fc Tag (HPLC-verified) |
|
Immobilized Cynomolgus NKG2D, His Tag (Cat. No. NKD-C5248) at 5 μg/mL (100 μL/well) can bind Human MICA, Fc Tag (Cat. No. MIA-H5253) with a linear range of 0.2-2 ng/mL (QC tested).
The purity of Biotinylated Human NKG2D Protein, Avitag,His Tag (Cat. No. NKD-H82Q3) is more than 85% and the molecular weight of this protein is around 36-46 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Tesnatilimab | IPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555 | Phase 2 Clinical | Innate Pharma | Alopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Inflammation; Crohn Disease | Details |
NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology) | Phase 2 Clinical | Coronavirus Disease 2019 (COVID-19) | Details | ||
QEQ-278 | QEQ-278 | Phase 1 Clinical | Novartis Pharmaceuticals Corp | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
NKG2D CAR-T Cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Colorectal Neoplasms; Leukemia, Myeloid, Acute | Details | |
NKG2D CAR-T cell therapy (Uwell Biopharma) | UWN2D | Clinical | Uwell Biopharma | Neoplasms | Details |
Tesnatilimab | IPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555 | Phase 2 Clinical | Innate Pharma | Alopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Inflammation; Crohn Disease | Details |
NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology) | Phase 2 Clinical | Coronavirus Disease 2019 (COVID-19) | Details | ||
QEQ-278 | QEQ-278 | Phase 1 Clinical | Novartis Pharmaceuticals Corp | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
NKG2D CAR-T Cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Colorectal Neoplasms; Leukemia, Myeloid, Acute | Details | |
NKG2D CAR-T cell therapy (Uwell Biopharma) | UWN2D | Clinical | Uwell Biopharma | Neoplasms | Details |
This web search service is supported by Google Inc.